Yvonne Briggs
Investor Relations (LHA)
Replay available
ENDRA Life Sciences Inc. (NASDAQ: NDRA) Q2 2024 earnings conference call, held 2024-08-22. Replay captured from the company's public earnings webcast.

Investor Relations (LHA)
Acting Chief Executive Officer
Head of Regulatory and Clinical Affairs
Chief Technology Officer
Chief Financial Officer
Analyst, Ascendant Capital
Good afternoon and welcome to the Endura Life Sciences second quarter 2024 financial results conference call. All participants will be in listen only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star, then two. Please note, this event is being recorded. I would now like to turn the conference over to Yvonne Briggs. Please go ahead. Yvonne Briggs Thank you, Operator. This is Yvonne Briggs with LHA. Good afternoon and welcome to Endra Life Sciences' second quarter 2024 Business Update and Financial Results conference call. Earlier today, Endra issued a press release on this topic, which is available in the Investors section of Endra's website. Before we begin, please note that today's discussion will include forward-looking statements, all statements by management other than statements of historical facts, including statements regarding the company's strategies, financial condition, operations, costs, plans, and objectives, as well as anticipated results of development and commercialization efforts, the timing of clinical studies, potential partnership opportunities, and expectations regarding regulatory processes, receipt of required regulatory clearances, and product launches are forward-looking statements. Except as required by federal securities laws, the company disclaims any obligation to update or revise any forward-looking statements. Please refer to the company's Form 10-K for the 2023 fiscal year and subsequent SEC filings for more information about risks and uncertainties related to forward-looking statem...